Shares of CureVac (CVAC) gained 7.7% in trading on Friday after the company said it plans to develop COVID-19 vaccine candidates that can prevent infection with new variants as part of an agreement with the United Kingdom. The U.K. has already agreed to take 50 million doses of the yet-to-be-identified variant vaccines. CureVac, which currently has an experimental COVID-19 vaccine in Phase 3 clinical trials in partnership with Bayer AG (BAYN), said it hopes to put new variant vaccine candidates into clinical trials in the U.K. CureVac this week also announced a research partnership with GlaxoSmithKline (GSK.LN) to develop new COVID-19 vaccines that can protect against some of the emerging variants of the virus. CureVac's stock is up 134.2% over the past three months, while the S&P 500 has gained 12.4%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
02-05-21 1042ETCopyright (c) 2021 Dow Jones & Company, Inc.